BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...to treat endogenous Cushing syndrome in adults. Recordati acquired worldwide rights to the inhibitor of CYP11B1...
...cancer 2 early onset; CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; CYP11B1 - Cytochrome P450 family 11 subfamily B polypeptide 1...
...1 early onset (BRCA1) Breast cancer 2 early onset (BRCA2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Epidermal...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
BioCentury | Aug 10, 2018
Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

...in the U.S and EU. The product is a 2S,4R-enantiomer of ketoconazole, an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1)...
...levoketoconazole Business: Endocrine/Metabolic Molecular target: Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1); CYP17A1; CYP21A2 Description: 2S,4R-enantiomer of ketoconazole, an inhibitor of CYP11B1...
...Additional Phase III data (1Q19); Phase III data (1Q19) Chris Lieu Recorlev, levoketoconazole (COR-003, COR003, NormoCort) Strongbridge Biopharma plc Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Cytochrome...
BioCentury | Oct 6, 2017
Financial News

NewLink, Strongbridge price follow-ons

...levoketoconazole to treat Cushing's syndrome. The therapy is a 2S,4R-enantiomer of ketoconazole, an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1)...
...Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Strongbridge Biopharma plc (NASDAQ:SBBP), Trevose, Pa. Jennie Walters Recorlev NewLink Genetics Corp. Strongbridge Biopharma plc CYP17A1 CYP21A2 Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Indoleamine...
BioCentury | Oct 4, 2017
Financial News

NewLink, Strongbridge price follow-ons

...of ketoconazole, an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) , CYP17A1 and CYP21A2 . Jennie Walters indoximod levoketoconazole NLG8189 Recorlev NewLink Genetics Corp. Strongbridge Biopharma plc Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Cytochrome...
BioCentury | Jan 25, 2016
Clinical News

Metyrapone/oxazepam: Phase I data

...Shreveport, La. Product: Metyrapone/oxazepam ( EMB-001 ) Business: Neurology Molecular target: GABA A receptor ; Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1)...
BioCentury | Oct 17, 2015
Financial News

Strongbridge raises $25M in U.S. listing

...from FDA and EMA, is a 2S,4R-enantiomer of ketoconazole , an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 ( CYP11B1...
BioCentury | Jun 15, 2015
Clinical News

Metyrapone/oxazepam: Phase I started

...Shreveport, La. Product: Metyrapone/oxazepam ( EMB-001 ) Business: Neurology Molecular target: GABA A receptor ; Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1)...
BioCentury | Oct 31, 2014
Financial News

Cortendo pulls Oslo IPO to mull U.S. listing, raises $11.3M

...NormoCort to treat Cushing's syndrome. The 2S,4R-enantiomer of ketoconazole , an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 ( CYP11B1...
Items per page:
1 - 10 of 16